All ImmunoGen articles
-
NewsAntibody-immunotherapy treatment shows benefit in serious endometrial cancer
The novel combination cancer therapy facilitated âexceptionalâ responses in some patients enrolled in a Phase II study for endometrial cancer.
-
NewsAbbVie announces its new CEO
During his tenure as AbbVieâs CEO, Richard Gonzalez successfully navigated the end of exclusivity for the biologic Humira in the US.
-
NewsAbbVie agrees $10 billion oncology acquisition
Under its proposed acquisition of ImmunoGen, AbbVie will gain rights to ELAHEREÂź, the first antibody-drug conjugate (ADC) approved in ovarian cancer.
-
ArticleAccelerating drug development
Here, Dave Elder explores how a âquick-approval, quick-withdrawal from the marketâ approach is used to accelerate drug development.